[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE0301998D0 - Quil A fraction with low toxicity and use thereof - Google Patents

Quil A fraction with low toxicity and use thereof

Info

Publication number
SE0301998D0
SE0301998D0 SE0301998A SE0301998A SE0301998D0 SE 0301998 D0 SE0301998 D0 SE 0301998D0 SE 0301998 A SE0301998 A SE 0301998A SE 0301998 A SE0301998 A SE 0301998A SE 0301998 D0 SE0301998 D0 SE 0301998D0
Authority
SE
Sweden
Prior art keywords
quil
fraction
adjuvant
lps
derivatives
Prior art date
Application number
SE0301998A
Other languages
English (en)
Inventor
Bror Morein
Karin Loevgren Bengtsson
Jill Ekstroem
Katarina Ranlund
Original Assignee
Isconova Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isconova Ab filed Critical Isconova Ab
Priority to SE0301998A priority Critical patent/SE0301998D0/sv
Publication of SE0301998D0 publication Critical patent/SE0301998D0/sv
Priority to DK04749076T priority patent/DK1648505T3/da
Priority to CA2529363A priority patent/CA2529363C/en
Priority to AT04749076T priority patent/ATE442164T1/de
Priority to NZ544299A priority patent/NZ544299A/en
Priority to AU2004254152A priority patent/AU2004254152B2/en
Priority to BRPI0412444A priority patent/BRPI0412444B8/pt
Priority to JP2006518582A priority patent/JP4731475B2/ja
Priority to ES04749076T priority patent/ES2331952T3/es
Priority to DE602004023089T priority patent/DE602004023089D1/de
Priority to PL04749076T priority patent/PL1648505T3/pl
Priority to EP04749076A priority patent/EP1648505B1/en
Priority to US10/562,866 priority patent/US8821881B2/en
Priority to PCT/SE2004/001038 priority patent/WO2005002620A1/en
Priority to ZA200600151A priority patent/ZA200600151B/en
Priority to US14/445,690 priority patent/US20140335049A1/en
Priority to US14/714,664 priority patent/US20150320858A1/en
Priority to US15/054,801 priority patent/US20160184427A1/en
Priority to US15/874,262 priority patent/US20180369368A1/en
Priority to US16/701,948 priority patent/US20200345840A1/en
Priority to US17/477,739 priority patent/US20220241408A1/en
Priority to US18/376,666 priority patent/US20240024468A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
SE0301998A 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof SE0301998D0 (sv)

Priority Applications (22)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof
PCT/SE2004/001038 WO2005002620A1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
PL04749076T PL1648505T3 (pl) 2003-07-07 2004-07-07 Frakcja Quil A o niskiej toksyczności i jej zastosowanie
US10/562,866 US8821881B2 (en) 2003-07-07 2004-07-07 Quil A fraction with low toxicity and use thereof
AT04749076T ATE442164T1 (de) 2003-07-07 2004-07-07 Quil a fraktion mit geringer toxizität und ihre verwendung
NZ544299A NZ544299A (en) 2003-07-07 2004-07-07 Quil A fraction A for the enhancement of immune activities and immunomodulating activities
AU2004254152A AU2004254152B2 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
BRPI0412444A BRPI0412444B8 (pt) 2003-07-07 2004-07-07 fração de quil a com baixa toxidez e seu uso
JP2006518582A JP4731475B2 (ja) 2003-07-07 2004-07-07 毒性の低いＱｕｉｌＡ画分およびその使用
ES04749076T ES2331952T3 (es) 2003-07-07 2004-07-07 Fraccion de quil a con baja toxicidad y su uso.
DE602004023089T DE602004023089D1 (de) 2003-07-07 2004-07-07 Quil a fraktion mit geringer toxizität und ihre verwendung
DK04749076T DK1648505T3 (da) 2003-07-07 2004-07-07 Quil A-fraktion med lav toksicitet og anvendelse deraf
EP04749076A EP1648505B1 (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
CA2529363A CA2529363C (en) 2003-07-07 2004-07-07 Quil a fraction with low toxicity and use thereof
ZA200600151A ZA200600151B (en) 2003-07-07 2006-01-06 Quil A fraction with low toxicity and use thereof
US14/445,690 US20140335049A1 (en) 2003-07-07 2014-07-29 Quil a fraction with low toxicity and use thereof
US14/714,664 US20150320858A1 (en) 2003-07-07 2015-05-18 Quil a fraction with low toxicity and use thereof
US15/054,801 US20160184427A1 (en) 2003-07-07 2016-02-26 Quil a fraction with low toxicity and use thereof
US15/874,262 US20180369368A1 (en) 2003-07-07 2018-01-18 Quil a fraction with low toxicity and use thereof
US16/701,948 US20200345840A1 (en) 2003-07-07 2019-12-03 Quil a fraction with low toxicity and use thereof
US17/477,739 US20220241408A1 (en) 2003-07-07 2021-09-17 Quil a fraction with low toxicity and use thereof
US18/376,666 US20240024468A1 (en) 2003-07-07 2023-10-04 Quil a fraction with low toxicity and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof

Publications (1)

Publication Number Publication Date
SE0301998D0 true SE0301998D0 (sv) 2003-07-07

Family

ID=27731119

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301998A SE0301998D0 (sv) 2003-07-07 2003-07-07 Quil A fraction with low toxicity and use thereof

Country Status (15)

Country Link
US (8) US8821881B2 (sv)
EP (1) EP1648505B1 (sv)
JP (1) JP4731475B2 (sv)
AT (1) ATE442164T1 (sv)
AU (1) AU2004254152B2 (sv)
BR (1) BRPI0412444B8 (sv)
CA (1) CA2529363C (sv)
DE (1) DE602004023089D1 (sv)
DK (1) DK1648505T3 (sv)
ES (1) ES2331952T3 (sv)
NZ (1) NZ544299A (sv)
PL (1) PL1648505T3 (sv)
SE (1) SE0301998D0 (sv)
WO (1) WO2005002620A1 (sv)
ZA (1) ZA200600151B (sv)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1104306T3 (da) * 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
BRPI0606481A2 (pt) * 2005-01-20 2009-06-30 Isconova Ab composição de vacina compreendendo uma proteìna de ligação a fibronectina ou um peptìdeo de ligação a fibronectina
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
AU2007231027B2 (en) 2006-03-24 2013-10-03 Novartis Influenza Vaccines Marburg Gmbh Storage of influenza vaccines without refrigeration
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP1902727A1 (de) * 2006-09-22 2008-03-26 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
WO2008031878A1 (en) * 2006-09-15 2008-03-20 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH A composition for therapy and/or for prophylaxis of hbv-infections and hbv-mediated diseases
CN101563090B (zh) * 2006-11-20 2013-01-02 杜科姆公司 包含南美皂皮树皂苷的含脂质颗粒用于治疗癌症的用途
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
EP3552625A1 (en) * 2008-06-27 2019-10-16 Zoetis Services LLC Novel adjuvant compositions
WO2011005183A1 (en) * 2009-07-10 2011-01-13 Isconova Ab New composition
CA2808556A1 (en) 2010-09-20 2012-03-29 Crucell Holland B.V. Therapeutic vaccination against active tuberculosis
AU2012319239B2 (en) 2011-10-03 2017-04-20 Mx Adjuvac Ab Nanoparticles, process for preparation and use thereof as carrier for amphipatic of hydrophobic molecules in fields of medicine including cancer treatment and food related compounds
US9452211B2 (en) 2011-11-28 2016-09-27 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
HUE027839T2 (en) 2012-03-12 2016-11-28 Crucell Holland Bv Recombinant adenoviruses with altered terminals
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
NZ630753A (en) 2012-03-22 2016-12-23 Janssen Vaccines & Prevention Bv Vaccine against rsv
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
JP6282673B2 (ja) 2013-03-08 2018-02-21 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 無細胞百日咳ワクチン
US9907846B2 (en) 2013-04-01 2018-03-06 Mx Adjuvac Ab Nanoparticles, composed of sterol and saponin from Quillaja saponaria Molina for use in pharmaceutical compositions
AU2014259474B2 (en) 2013-04-25 2018-09-13 Janssen Vaccines & Prevention B.V. Stabilized soluble prefusion RSV F polypeptides
MY190097A (en) 2013-05-30 2022-03-28 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
WO2015000832A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
NZ733383A (en) 2013-09-19 2022-12-23 Zoetis Services Llc Oil-based adjuvants
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
MY187261A (en) 2014-07-10 2021-09-16 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
NZ730802A (en) 2014-11-04 2021-12-24 Janssen Vaccines & Prevention Bv Therapeutic hpv16 vaccines
EP4248992A3 (en) 2015-01-16 2023-12-27 Zoetis Services LLC Foot-and-mouth disease vaccine
PL3283634T3 (pl) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Rekombinowany adenowirus eksprymujący dwa transgeny z dwukierunkowym promotorem
IL288541B (en) 2015-07-07 2022-08-01 Janssen Vaccines Prevention B V vaccine against rsv
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
JP6470872B2 (ja) 2015-08-20 2019-02-13 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１８ワクチン
EP3344288A1 (en) 2015-09-02 2018-07-11 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
IL257800B2 (en) 2015-09-03 2023-11-01 Novavax Inc Immune compositions with improved stability and immunogenicity
IL260203B2 (en) 2015-12-23 2024-09-01 Pfizer Protein mutants of RSV F
KR102401247B1 (ko) 2016-04-05 2022-05-25 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
JP7053491B2 (ja) 2016-05-02 2022-04-12 ヤンセン ファッシンズ アンド プリベンション ベーフェー 治療用ｈｐｖワクチン組み合わせ
DE202016003070U1 (de) 2016-05-09 2016-06-07 Clariant International Ltd. Stabilisatoren für Silikatfarben
RU2758238C2 (ru) 2016-05-12 2021-10-26 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
MY194419A (en) 2016-05-30 2022-11-30 Janssen Vaccines & Prevention Bv Stabilized pre-fusion rsv f proteins
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
US10744196B2 (en) 2016-07-14 2020-08-18 Janssen Vaccines & Prevention B.V. HPV vaccines
DE112017005577T5 (de) 2016-11-04 2019-08-29 Cabot Corporation Nanokomposite, enthaltend kristallinen Polyester und Organosiliciumdioxid
MX2019009316A (es) 2017-02-09 2019-09-19 Janssen Vaccines & Prevention Bv Promotor corto y potente para la expresion de genes heterologos.
JP2020519663A (ja) 2017-05-17 2020-07-02 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
KR20200053518A (ko) 2017-09-15 2020-05-18 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 면역의 안전한 유도를 위한 방법
SI3743106T1 (sl) 2018-01-23 2022-10-28 Janssen Vaccines & Prevention B. V. Cepiva proti virusu influence in njihove uporabe
KR20210004959A (ko) 2018-03-19 2021-01-13 노바백스, 인코포레이티드 다가 인플루엔자 나노입자 백신
GB201807303D0 (en) 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
EP3880243A1 (en) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
KR20220005002A (ko) 2019-04-25 2022-01-12 얀센 백신스 앤드 프리벤션 비.브이. 재조합 인플루엔자 항원
WO2020229577A1 (en) 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
CN113950333A (zh) 2019-05-15 2022-01-18 扬森疫苗与预防公司 使用基于腺病毒的疫苗预防性治疗呼吸道合胞病毒感染
JP2022547107A (ja) 2019-09-05 2022-11-10 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
EP4097122A4 (en) 2020-01-31 2024-07-17 Beth Israel Deaconess Medical Ct Inc COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CORONAVIRUS INFECTION - SARS-COV-2 VACCINES
JP2023524879A (ja) 2020-05-11 2023-06-13 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化されたコロナウイルススパイクタンパク質融合タンパク質
US20210347828A1 (en) 2020-05-11 2021-11-11 Janssen Pharmaceuticals, Inc. RNA Replicon Encoding a Stabilized Corona Virus Spike Protein
MX2022014161A (es) 2020-05-11 2022-12-02 Janssen Pharmaceuticals Inc Vacunas contra sars-cov-2.
CN116096406A (zh) 2020-06-29 2023-05-09 扬森疫苗与预防公司 针对呼吸道合胞病毒感染的疫苗组合
JP2023532369A (ja) 2020-07-06 2023-07-27 ヤンセン ファーマシューティカルズ，インコーポレーテッド 安定化されたコロナウイルススパイクタンパク質融合タンパク質
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
WO2022175479A1 (en) 2021-02-19 2022-08-25 Janssen Vaccines & Prevention B.V. Vaccine combinations against respiratory syncytial virus strain a and b infections
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
KR20230147156A (ko) 2021-02-19 2023-10-20 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합 전 rsv fb 항원
AU2022249741A1 (en) 2021-04-01 2023-09-21 Msd International Business Gmbh Stabilized pre-fusion piv3 f proteins
WO2023020939A1 (en) 2021-08-17 2023-02-23 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023047348A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized corona virus spike protein fusion proteins
WO2023047349A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceuticals, Inc. Stabilized coronavirus spike protein fusion proteins
WO2023111725A1 (en) 2021-12-14 2023-06-22 Janssen Pharmaceuticals, Inc. Sars-cov-2 vaccines
WO2023110618A1 (en) 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2023217988A1 (en) 2022-05-12 2023-11-16 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
WO2024017682A1 (en) 2022-07-18 2024-01-25 Janssen Vaccines & Prevention B.V. Rsv immunogens
US20240042021A1 (en) 2022-08-01 2024-02-08 Flagship Pioneering Innovations Vii, Llc Immunomodulatory proteins and related methods
WO2024061753A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized trimeric class i fusion proteins
WO2024061759A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Stabilized coronavirus s proteins
WO2024061757A1 (en) 2022-09-23 2024-03-28 Janssen Vaccines & Prevention B.V. Pre-fusion human piv1 f proteins
WO2024074584A1 (en) 2022-10-06 2024-04-11 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion piv3 f proteins
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024154048A1 (en) 2023-01-18 2024-07-25 Pfizer Inc. Vaccines against respiratory diseases
US20240269263A1 (en) 2023-02-06 2024-08-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory compositions and related methods
WO2024175579A1 (en) 2023-02-21 2024-08-29 Janssen Vaccines & Prevention B.V. Stabilized trimeric rsv fusion proteins without a heterologous trimerzation domain

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5839376B2 (ja) * 1978-10-30 1983-08-30 富士通株式会社 イオン注入法
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE71303T1 (de) * 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) * 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) * 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
SE9600647D0 (sv) * 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
US6558670B1 (en) * 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) * 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof

Also Published As

Publication number Publication date
US20060239963A1 (en) 2006-10-26
ATE442164T1 (de) 2009-09-15
US20200345840A1 (en) 2020-11-05
CA2529363A1 (en) 2005-01-13
PL1648505T3 (pl) 2010-02-26
JP2007527386A (ja) 2007-09-27
US20180369368A1 (en) 2018-12-27
AU2004254152B2 (en) 2009-10-29
BRPI0412444B8 (pt) 2021-05-25
US20160184427A1 (en) 2016-06-30
CA2529363C (en) 2013-04-02
AU2004254152A1 (en) 2005-01-13
WO2005002620A1 (en) 2005-01-13
ES2331952T3 (es) 2010-01-21
BRPI0412444A (pt) 2006-09-19
US20220241408A1 (en) 2022-08-04
ZA200600151B (en) 2007-01-31
US20140335049A1 (en) 2014-11-13
DK1648505T3 (da) 2009-12-21
BRPI0412444B1 (pt) 2016-06-14
US20240024468A1 (en) 2024-01-25
DE602004023089D1 (de) 2009-10-22
US20150320858A1 (en) 2015-11-12
EP1648505A1 (en) 2006-04-26
EP1648505B1 (en) 2009-09-09
US8821881B2 (en) 2014-09-02
NZ544299A (en) 2009-03-31
JP4731475B2 (ja) 2011-07-27

Similar Documents

Publication Publication Date Title
SE0301998D0 (sv) Quil A fraction with low toxicity and use thereof
MX2011012836A (es) Adyuvantes sinteticos de glucopiranosil-lipido.
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
WO2007109812A3 (en) Immunopotentiating compounds
MY165643A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
WO2006086449A3 (en) Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
NO20064781L (no) Fremgangsmater og adjuvanser for a forbedre immunresponser mot vaksiner og fremgangsmater for anvendelse
HK1132934A1 (en) Vaccine composition containing synthetic adjuvant
BRPI0607840A2 (pt) uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit
NO20070746L (no) Anvendelse av fosfaterte alkanoler som dispergente , emulgatorer, hydrotroper, fuktmidler og kompatabilitetsstoffer i blandinger for jordbruket.
BRPI0511026A (pt) uso de um los neisserial, e, composição
MX2009011384A (es) Combinaciones adyuvantes que comprenden un activador de nkt, un agonista de cd40 y opcionalmente un antígeno y uso de las mismas para inducir un aumento sinergístico en la inmunidad celular.
WO2006114680A8 (en) Vaccine adjuvants
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CU23305B7 (es) Compuesto polisacã rido con actividad inmunoestimulante
RU2002112709A (ru) Способ предпосевной обработки семян